Tag: tumor mutational burden

Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers

sarah JonasResearch Results

A high rate of genetic mutations within a tumor, known as high tumor mutation burden, was only useful for predicting immunotherapy responses in a subset of cancer types, suggesting that this may not reliably be used as a universal biomarker.

Multimodal Genomic Analyses Predict Response to Immunotherapy in Lung Cancer Patients

sarah JonasResearch Results

Researchers at Johns Hopkins Kimmel Cancer Center, the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine have developed an integrated genomic approach that potentially could help physicians predict which patients with nonsmall cell lung cancer will respond to therapy with immune checkpoint inhibitors.